Login
Revolution Medicines, Inc. logo

Revolution Medicines, Inc.

revmed.com

What Do They Do?

Develops targeted medicines for patients with cancers driven by RAS mutations, including pancreatic, lung and colorectal cancers.

Who Are Their Customers?

The company works with collaborators through agreements covering licenses and research and development, which may also include product delivery and other joint work.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
vs $0 in Q3 FY2025
Net income
▼ −34% (Loss)
vs −$305.2M in Q3 FY2025
  • Aug 26, 2026 FDA approved RASONQUE for metastatic pancreatic cancer Once-daily tablets are available in the United States for eligible patients.

Pipeline focus The older report described RAS inhibitors alongside companion inhibitors aimed at other signaling pathway targets. The latest report describes a pipeline centered on RAS inhibitors.

Who Do They Compete With?

Competes with Amgen, Betta Pharmaceuticals, BMS, Chengdu Huajian Future Technology, D3 BIO, Eli Lilly, GenEros Biopharma, GenFleet Therapeutics, Genhouse Bio, Guangzhou BeBetter Medicine Technology, HUYA Bioscience, InventisBio, Jacobio Pharmaceuticals, Jiangsu Hansoh Pharmaceutical Group, Merck, Sharpe & Dohme, Roche/Genentech, BridgeBio Pharma, Frontier Medicines, AstraZeneca, and Incyte

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support